Income Statement Protagonist Therapeutics, Inc.
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.79 USD | +1.07% |
|
+0.05% | -2.92% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 28.63M | 27.36M | 26.58M | 60M | 434M | |||||
Total Revenues | 28.63M | 27.36M | 26.58M | 60M | 434M | |||||
Gross Profit | 28.63M | 27.36M | 26.58M | 60M | 434M | |||||
Selling General & Admin Expenses, Total | 18.64M | 27.2M | 31.74M | 33.49M | 43.46M | |||||
R&D Expenses | 74.51M | 126M | 126M | 120M | 138M | |||||
Other Operating Expenses, Total | 93.14M | 153M | 158M | 154M | 182M | |||||
Operating Income | -64.52M | -126M | -131M | -93.65M | 253M | |||||
Interest Expense, Total | -598K | - | - | - | - | |||||
Interest And Investment Income | 900K | 443K | 4.06M | 14.9M | 26.32M | |||||
Net Interest Expenses | 302K | 443K | 4.06M | 14.9M | 26.32M | |||||
Currency Exchange Gains (Loss) | -46K | -149K | -80K | -201K | 250K | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | -64.26M | -126M | -127M | -78.96M | 279M | |||||
Other Unusual Items | -585K | - | - | - | - | |||||
EBT, Incl. Unusual Items | -64.84M | -126M | -127M | -78.96M | 279M | |||||
Income Tax Expense | 1.3M | - | - | - | 4.22M | |||||
Earnings From Continuing Operations | -66.15M | -126M | -127M | -78.96M | 275M | |||||
Net Income to Company | -66.15M | -126M | -127M | -78.96M | 275M | |||||
Net Income - (IS) | -66.15M | -126M | -127M | -78.96M | 275M | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | -66.15M | -126M | -127M | -78.96M | 275M | |||||
Net Income to Common Excl. Extra Items | -66.15M | -126M | -127M | -78.96M | 275M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -1.92 | -2.71 | -2.6 | -1.39 | 4.47 | |||||
Basic EPS - Continuing Operations | -1.92 | -2.71 | -2.6 | -1.39 | 4.47 | |||||
Basic Weighted Average Shares Outstanding | 34.4M | 46.32M | 49.04M | 56.76M | 61.57M | |||||
Net EPS - Diluted | -1.92 | -2.71 | -2.6 | -1.39 | 4.23 | |||||
Diluted EPS - Continuing Operations | -1.92 | -2.71 | -2.6 | -1.39 | 4.23 | |||||
Diluted Weighted Average Shares Outstanding | 34.4M | 46.32M | 49.04M | 56.76M | 65.08M | |||||
Normalized Basic EPS | -1.17 | -1.69 | -1.62 | -0.87 | 2.84 | |||||
Normalized Diluted EPS | -1.17 | -1.69 | -1.62 | -0.87 | 2.68 | |||||
Supplemental Items | ||||||||||
EBITDA | -63.73M | -125M | -130M | -92.68M | 254M | |||||
EBITA | -64.52M | -126M | -131M | -93.65M | 253M | |||||
EBIT | -64.52M | -126M | -131M | -93.65M | 253M | |||||
EBITDAR | -62.04M | -123M | -128M | -90.48M | 256M | |||||
Effective Tax Rate - (Ratio) | -2.01 | - | - | - | 1.51 | |||||
Current Domestic Taxes | - | - | - | - | 4.22M | |||||
Current Foreign Taxes | -88K | - | - | - | - | |||||
Total Current Taxes | -88K | - | - | - | 4.22M | |||||
Deferred Foreign Taxes | 1.39M | - | - | - | - | |||||
Total Deferred Taxes | 1.39M | - | - | - | - | |||||
Normalized Net Income | -40.16M | -78.47M | -79.62M | -49.35M | 175M | |||||
Interest on Long-Term Debt | 698K | - | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 18.64M | 27.2M | 31.74M | 33.49M | 43.46M | |||||
Research And Development Expense From Footnotes | 75.98M | 129M | 126M | 120M | 138M | |||||
Net Rental Expense, Total | 1.69M | 1.87M | 2.21M | 2.2M | 2.48M | |||||
Imputed Operating Lease Interest Expense | 702K | - | - | - | - | |||||
Imputed Operating Lease Depreciation | 983K | - | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 4.12M | 9M | 14.72M | 17.06M | 20.92M | |||||
Stock-Based Comp., G&A Exp. (Total) | 3.78M | 7.4M | 9.48M | 12.23M | 16.64M | |||||
Total Stock-Based Compensation | 7.9M | 16.4M | 24.2M | 29.29M | 37.55M |
- Stock Market
- Equities
- PTGX Stock
- Financials Protagonist Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















